ERBB2 and congenital rubella syndrome: Many trials, notably CAR T trials targeting HER2 (NCT04650451), Claudin 18.2 (NCT03874897), GD2 (NCT03373097), PSCA (NCT02744287), and PSMA (NCT04249947, (NCT03089203), reported that patients experienced CRS (regardless of severity).